The Utah Jazz have an exciting night tomorrow because they have the 10th, 29th, and 32nd pick in the 2024 NBA Draft. the Jazz have been in several rumors regarding the draft. Some rumors suggest the Jazz will trade up for higher than pick number 10. Some rumors suggest the Jazz will package picks 29 and 32 for a higher second pick in the first round. The honest observation at this point is that the Jazz might do just about anything for the draft. Tune in tomorrow night from home or from the Delta Center to find out what the Jazz do in round one! To watch the draft, tune in to ABC or ESPN.

Round One Draft: 6 PM MST, June 26th

Round Two Draft: 2 PM MST, June 27th

Below are projections on who the Jazz could select with their 3 picks. The projections are based on the Jazz’s rumored interest and generally where players are projected to be picked.

10th Pick Projections:

Ron Holland

Nikola Topic

Rob Dillingham

Cody Williams

Zach Edey

Dalton Knecht

29th Pick Projections:

Advertisement

Photo by Jeff Haynes/NBAE via Getty Images

Advertisement

Kyshawn George

Ryan Dunn

Baylor Scheierman

AJ Johnson

Justin Edwards

Cam Christie

Tyler smith

Johnny Furphy

Advertisement

Photo by Ryan M. Kelly/Getty Images

Advertisement

Pick 32 Projections:

Picks 29 and 32 are close so these projections mainly overlap.

Harrison Ingram

Kyle Flipowski

Trentyn Flowers

Jonathan Mogbo

Jaylon Tyson

Tyler Kolek

Bronny James

Bobi Klintman

Final Prediction

This projection could be way off because this draft has a lot of parity and the Jazz could very well trade some of their picks. With that said, I predict that the Jazz select Nikola Topic with the 10th pick. For the 29th pick, The Jazz go for Ryan Dunn. For the 32nd pick, I predict that the Jazz select Jaylon Tyson. I think the Jazz will almost make a trade or two tomorrow but don’t quite pull the trigger.

What do you think the Jazz will do tomorrow night? Comment below!

The Tribune’s Andy Larsen breaks down the latest reports.

The NBA Draft starts Wednesday, and the rumor mill is heating up around the Utah Jazz. Here’s the latest news, along with my reaction to the possibilities.

Trading for Mikal Bridges?

Rumor: Yahoo’s Jake Fischer reported that the Jazz are one of the teams interested in trading for Brooklyn wing Mikal Bridges, along with Houston and New York. Bridges is one of “Utah’s most aggressive aspirations,” Fischer wrote.

Reaction: The Nets have repeatedly declined to trade Bridges despite it probably making sense for the franchise to do so. Instead, they’ve been asking for more than three first-round picks in return for the 27-year-old.

Bridges would make the Jazz significantly better; he’s developed himself into a 20-point-per-game scorer while also being a solid defender. He’s the two-way player with size that these most recent playoffs have shown are extremely valuable. (Though we should note here that he was a far better player before the All-Star break than after it last year.)

The problem is that it’s not immediately clear that the Jazz would be a playoff team even with Bridges — he was an eight-win player last season, and the Jazz finished 15 wins short of the No. 10 seed. For an acquisition of Bridges to make sense, Utah would probably need to acquire other good players around him and Lauri Markkanen to get up in that 45-win range required to make the playoffs in the West. Still, it could be an exciting first step.

Trading for Zach LaVine?

Rumor: The Bulls “remain active” on trade negotiations sending out Zach LaVine involving the Jazz and the Philadelphia 76ers, according to NBC Sports Chicago’s K.C. Johnson. However, reporter Marc Stein disagreed with the report, saying he had been “advised to dismiss Utah’s interest.”

Reaction: Johnson’s a quality veteran reporter, but I agree with Stein. While I haven’t heard recent updates, Jazz personnel earlier this year indicated that LaVine wasn’t a logical option in the pre-trade deadline market given the Jazz’s place in the standings, LaVine’s poor record of availability, and especially his high contract that pays him a combined $138 million over the next three years.

I don’t suspect circumstances have changed enough since to make a LaVine trade make sense now, at least not a trade in which the Jazz are giving up assets. If anything, it might require Chicago to send out assets to push the Jazz to take on LaVine’s deal.

Signing Tobias Harris?

Rumor: The Athletic’s Shams Charania reported that the Jazz and the Detroit Pistons “are expected to be the strongest suitors for Tobias Harris,” who is a free agent this summer after his 5-year, $180 million albatross of a deal ended with the 76ers.

Reaction: The Jazz will likely have about $40 million in cap space this summer. Some of that room the franchise anticipates using on Markkanen’s renegotiation and extension as the Finnish star enters the final year of his current contract.

Harris is theoretically someone who could help the Jazz. At this point in his career, he’s statistically pretty average across the board — his shooting, rebounding, passing, steals, and block rates are just around the 50th percentile, maybe a bit higher. Even average, though, would make Harris the Jazz’s best wing by a lot.

He turns 32 this summer, so Harris doesn’t make sense for the Jazz’s long-term future, and signing him would also mean fewer minutes for last year’s No. 9 pick, Taylor Hendricks. But if they could get him on a short-term deal for a discount, he could also be a tradable piece in a move later while helping the Jazz improve now.

Looking to move up?

Rumor: Multiple reporters indicated that the Jazz are looking to move up in the draft using the No. 29 pick and the No. 32 pick. First, ESPN’s Jonathan Givony reported Monday morning that the Jazz are looking to trade the two picks for a “pick in the late teens.” Arizona sports radio host John Gambadoro reported that he believed that the Suns had had discussions with the Jazz, sending the No. 22 pick to Utah for No. 29 and No. 32. Fischer, meanwhile, floated the idea of the Jazz acquiring No. 17 from the Lakers in exchange for the two picks.

Reaction: Jazz general manager Justin Zanik acknowledged that the club has reservations about having six first- or second-year players on the roster next season, the logical outcome if the team makes all three selections on Wednesday. So the Jazz consolidating these picks in this fashion follows that line of thinking, especially if they are targeting a player they believe is significantly better than what’s available around the turn of the draft.

My only concern is that, in general, teams trading up in drafts get a little less value than those trading down when you study the issue analytically. The NBA Draft Pick Trade Simulator at nbasense.com is a good tool for looking at this — trading No. 29 and No. 32 for No. 17 is a pretty fair deal, but trading those picks for No. 22 would be analytically a bad idea. That’s especially true in a “flat” draft, where players’ values are considered pretty close throughout the first round.

If the Jazz are going to defy the analytics, they should be really sure that the player they’re acquiring with the higher pick is worth giving up two chances to place bets further down in the draft.

Editor’s note • This story is available to Salt Lake Tribune subscribers only. Thank you for supporting local journalism.

TriSalus Life Sciences (NASDAQ:TLSI – Get Free Report) and Utah Medical Products (NASDAQ:UTMD – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings and valuation.

Profitability

This table compares TriSalus Life Sciences and Utah Medical Products’ net margins, return on equity and return on assets.

Risk & Volatility

TriSalus Life Sciences has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500. Comparatively, Utah Medical Products has a beta of 0.14, meaning that its stock price is 86% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for TriSalus Life Sciences and Utah Medical Products, as provided by MarketBeat.

TriSalus Life Sciences presently has a consensus target price of $13.33, indicating a potential upside of 129.10%. Given TriSalus Life Sciences’ higher probable upside, research analysts plainly believe TriSalus Life Sciences is more favorable than Utah Medical Products.

Earnings & Valuation

This table compares TriSalus Life Sciences and Utah Medical Products’ gross revenue, earnings per share and valuation.

Utah Medical Products has higher revenue and earnings than TriSalus Life Sciences.

Institutional and Insider Ownership

2.6% of TriSalus Life Sciences shares are held by institutional investors. Comparatively, 69.6% of Utah Medical Products shares are held by institutional investors. 76.2% of TriSalus Life Sciences shares are held by insiders. Comparatively, 6.6% of Utah Medical Products shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Utah Medical Products beats TriSalus Life Sciences on 6 of the 11 factors compared between the two stocks.

About TriSalus Life Sciences

(Get Free Report)

TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.

About Utah Medical Products

(Get Free Report)

Utah Medical Products, Inc. develops, manufactures, and distributes medical devices for the healthcare industry worldwide. It offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD infant respiratory hoods; and DELTRAN PLUS blood pressure monitoring systems. It also provides GESCO, an umbilical vessel catheters, including DIALY-NATE disposable peritoneal dialysis sets; PALA-NATE silicone oral protection devices; URI-CATH urinary drainage systems; NUTRI-CATHNUTRI-LOK feeding device; PICC-NATE, a percutaneous intraepithelial central venous catheter; MYELO-NATE lumbar sampling kits; HEMO-NATE disposable filters; and catheterization procedure tray of instruments and supplies. In addition, the company offers LETZ system to excise cervical intraepithelial neoplasia and other lower genital tract lesions; loop, ball, and needle electrodes; FILTRESSE evacuators; other specialty electrodes and supplies, and gynecologic tools; Femcare trocars, cannulae, laparoscopic instruments, and accessories; and EPITOME and OptiMicro electrosurgical devices. Further, it provides Filshie Clip female surgical contraception devices; PATHFINDER PLUS, an endoscopic irrigation devices; suprapubic catheterization; LIBERTY, an urinary incontinence treatment and control systems; ENDOCURETTE, a curette for uterine endometrial tissue sampling; TVUS/HSG-Cath to assess abnormal or dysfunctional uterine bleeding and other abnormalities of uterus; and LUMIN, a tool to manipulate the uterus in laparoscopic procedures. Additionally, it offers DELTRAN, a disposable pressure transducer; high-pressure and piezo-resistive transducer assemblies; and pressure monitoring accessories, components, and other molded parts. It serves neonatal intensive care units, labor and delivery departments, women’s health centers in hospitals, outpatient clinics, and physician’s offices. The company was incorporated in 1978 and is headquartered in Midvale, Utah.

Receive News & Ratings for TriSalus Life Sciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for TriSalus Life Sciences and related companies with MarketBeat.com’s FREE daily email newsletter.